Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys

Human and Experimental Toxicology

Volumn 23, Issue 5, 2004, Pages 219-227

  Arteaga Pérez, María E ^a   Maceira, M ^b   Casacó Parada, Angel ^b   Hernandez Sosa O ^a   Bada Barro, Ana M ^a   Leon Goni A ^a   Orphee Suarez R ^a   Cuevas Fiallo, A ^a   Moreno Diaz D ^a   Padro Gutierrez P ^c   Baro Gonzalez F ^c   Rodriguez Rodriguez V ^c   Charoo Ruiz, L ^c   Vasquez Castro F ^d   Ballester Labrada, A ^c   Cedeno M ^b  

^a CENPALAB   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^d Medical Surgical Research Center   (Cuba)

Author keywords

Cancer treatment; h R3; Monoclonal antibody; Nonhuman primates; Toxicity

Indexed keywords

AVIDIN; BIOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PEROXIDASE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BODY WEIGHT; CELL COUNT; CERCOPITHECUS; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; ELECTRONEUROLOGY; FEMALE; HEART RIGHT VENTRICLE FAILURE; HEMATOMA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MULTIPLE DRUG DOSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SKIN BIOPSY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; HEMATOMA; HEMORRHAGE; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAVENOUS; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; TOXICITY TESTS;

ANIMALIA; CERCOCEBUS; CERCOPITHECUS; CERCOPITHECUS AETHIOPS; CERCOPITHECUS AETHIOPS SABAEUS; PRIMATES;

EID: 3042548569     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327104ht438oa     Document Type: Article

References (21)

1. Ministerio de Salud Pública. Registro Nacional de Cáncer en Cuba 1997-1998. La Habana: Instituto Nacional de Oncología y Radiología, 2001.
2. Ministerio de Salud Pública. República de Cuba. Annual Health Statistics Report. La Habana, 1999.
3. Gavilondo CJ. Anticuerpos monoclonales producción y aplicaciones. Rev Cabana Inv Biomédicas 1989; 3: 98-111.
4. Fernández A, Perez R, Macias A, Velandia A, Alvarez I, Ramos M, Veloso A. Generación y caracterización primaria de anticuerpos monoclonales contra el receptor del factor de crecimiento epidérmico. Interferón Biotecnol 1989; 6: 289-99.
5. Fernandez A, Spitzer E, Perez R, Boehmer FD, Eckert K, Zschiesche W, Grosse R. A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections. J Cell Biochem 1992; 49: 157-65.
6. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3: 71-81.
7. Iznaga-Escobar N, Torres LA, Morales A, Ramos M, Alvarez I, Perez N, Fraxedas R, Rodriguez O, Rodriguez N, Perez R, Lage A, Stabin MG. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy. J Nucl Med 1998; 39: 15-23.
8. Crombet T, Torres O, Rodriguez V, Menendez A, Stevenson A, Ramos M, Torres F, Figueredo R, Veitia I, Iznaga N, Perez R, Lage A. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 2001; 20: 131-36.
9. Crombet T, Torres O, Neninger E, Catala M, Rodriguez N, Ramos M, Fernandez E, Iznaga N, Perez R, Lage A. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 2001; 16: 93-102.
10. Crombet T, Torres L, Neninger E, Catala M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Perez R, Lage A. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003; 26: 139-48.
11. Hibbs ML. Mouse EGFr. EMBL database, Accession code X78987.1.
12. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. EMBL database. Accession code X00588.1, Nature 1984; 309: 418-25.
13. Petch LA, Harris J, Raymond VW, Blasband A, Lee DC, Earp HS. A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue. (PIR database. Accession code A36325) Mol Cell Biol 1990; 10: 2973-82.
14. Kimyai-Asadi A, Jib MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody Cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138: 129-31.
15. Uckun FM, Yanishevski Y, Tumer N, Waurzyniak B, Messinger Y, Chelstrom LM, Lisowski EA, Ek O, Zeren T, Wendorf H, Langlie MC, Irvin JD, Myers DE, Fuller GB, Evans W, Gunther R. Pharmacokinetic features, immunogenicity, and toxicity of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin in Cynomolgus monkeys. Clin Cancer Res 1997; 3; 325-37.
16. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen, Henegouwen P. The epidermal growth factor. Cell Biol Int 1995; 19: 413-30.
17. Cohen S. Isolation of a submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J Biol Chem 1962; 237: 1555-62.
18. Carpenter G, Zendegui JG. Epidermal growth factor, its receptor, and related proteins. Exp Cell Res 1986; 164: 1-10.
19. Fransson J, Hammar H. Epidermal growth in the skin equivalent. Arch Dermatol Res 1992; 284: 343-48.
20. Points to consider in the manufacture and testing of monoclonal antibody products for human use. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 1997.
21. ICH Harmonized Tripartite Guideline. Preclinical safety evaluation biotechnology-derived pharmaceuticals, 1997.